Disseminated fungal infection in a patient receiving zanubrutinib

Abstract

Key Clinical Message We report a case of fatal disseminated aspergillosis in the setting of administration of zanubrutinib, a second‐generation Bruton's tyrosine kinase inhibitor thought to have a lower rate of immunosuppression‐related side effects.

Keywords

• aspergillus
• ibrutinib
• lymphoma
• zanubrutinib